Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in Patients with B-Cell Non-Hodgkin’s Lymphoma: A Single-Center Cohort Study

Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in Patients with B-Cell Non-Hodgkin’s Lymphoma: A Single-Center Cohort Study

It has been suggested that the effect of coronavirus disease 2019 (COVID-19) booster vaccination in patients with B-cell non-Hodgkin’s lymphoma (B-NHL) is inferior to that in healthy individuals. However, differences according to histological subtype or treatment status are unclear. In addition, the...

Full description

Bibliographic Details
Main Authors: Makoto Saito, Akio Mori, Takashi Ishio, Mirei Kobayashi, Shihori Tsukamoto, Sayaka Kajikawa, Emi Yokoyama, Minoru Kanaya, Koh Izumiyama, Haruna Muraki, Masanobu Morioka, Takeshi Kondo
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Viruses
Subjects:
B-cell non-Hodgkin’s lymphoma
COVID-19 mRNA vaccine
booster effect
breakthrough infection
Omicron variant
Online Access:https://www.mdpi.com/1999-4915/16/3/328

Internet

https://www.mdpi.com/1999-4915/16/3/328

Similar Items